ZA201306514B - Novel glucagon analogues - Google Patents
Novel glucagon analoguesInfo
- Publication number
- ZA201306514B ZA201306514B ZA2013/06514A ZA201306514A ZA201306514B ZA 201306514 B ZA201306514 B ZA 201306514B ZA 2013/06514 A ZA2013/06514 A ZA 2013/06514A ZA 201306514 A ZA201306514 A ZA 201306514A ZA 201306514 B ZA201306514 B ZA 201306514B
- Authority
- ZA
- South Africa
- Prior art keywords
- glucagon analogues
- novel glucagon
- novel
- analogues
- glucagon
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161468285P | 2011-03-28 | 2011-03-28 | |
| EP11159967 | 2011-03-28 | ||
| EP11182475 | 2011-09-23 | ||
| US201161539128P | 2011-09-26 | 2011-09-26 | |
| PCT/EP2012/055481 WO2012130866A1 (en) | 2011-03-28 | 2012-03-28 | Novel glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201306514B true ZA201306514B (en) | 2014-05-28 |
Family
ID=46929510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/06514A ZA201306514B (en) | 2011-03-28 | 2013-08-29 | Novel glucagon analogues |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20140031278A1 (https=) |
| EP (1) | EP2691108A1 (https=) |
| JP (1) | JP2014510739A (https=) |
| KR (1) | KR20140020292A (https=) |
| CN (1) | CN103596583B (https=) |
| AU (1) | AU2012234276A1 (https=) |
| BR (1) | BR112013024076A2 (https=) |
| CA (1) | CA2830974A1 (https=) |
| IL (1) | IL227869A0 (https=) |
| MX (1) | MX2013011175A (https=) |
| RU (1) | RU2013145013A (https=) |
| WO (1) | WO2012130866A1 (https=) |
| ZA (1) | ZA201306514B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8515257B2 (en) * | 2007-10-17 | 2013-08-20 | International Business Machines Corporation | Automatic announcer voice attenuation in a presentation of a televised sporting event |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2012311484B2 (en) * | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| IN2015DN00544A (https=) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| EP2986313B1 (en) | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AR098616A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MX2016010599A (es) | 2014-02-18 | 2016-11-18 | Novo Nordisk As | Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| BR112017014994B1 (pt) | 2015-02-17 | 2023-12-19 | Eli Lilly And Company | Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US10987426B2 (en) * | 2017-12-07 | 2021-04-27 | Adocia | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid |
| US20210030847A1 (en) * | 2018-01-23 | 2021-02-04 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| CA3128922A1 (en) * | 2019-02-05 | 2020-08-13 | Eli Lilly And Company | Glucagon analog agonists and methods of using the same |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| EP0876379A1 (en) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| JP2000514041A (ja) | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
| DE69727837T2 (de) | 1997-05-02 | 2004-12-30 | Dr. Reddy's Research Foundation, Hyderabad | Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| RU2215004C2 (ru) | 1997-07-16 | 2003-10-27 | Ново Нордиск А/С | Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| EP0971917B1 (en) | 1997-12-02 | 2002-02-06 | Dr. Reddy's Research Foundation | Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties |
| EP1123292A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| JP2002527502A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの調製及び使用 |
| US6353018B1 (en) | 1998-10-21 | 2002-03-05 | Novo Nordisk A/S | Compounds, their preparation and use |
| JP2002527507A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物類、それらの調製及び使用 |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| CZ20011831A3 (cs) | 1998-12-18 | 2001-10-17 | Novo Nordisk A/S | Kondenzované 1,2,4-thiadiazinové deriváty, jejich příprava a pouľití |
| WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| WO2000042023A1 (en) | 1999-01-18 | 2000-07-20 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| WO2000063191A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| PL351492A1 (en) | 1999-04-16 | 2003-04-22 | Reddys Lab Ltd Dr | Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them |
| WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
| WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
| EP1171414A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
| WO2000063190A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| DE60111534T2 (de) | 2000-07-20 | 2006-05-11 | F. Hoffmann-La Roche Ag | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| CA2531988C (en) * | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| TWI362392B (en) * | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US8603972B2 (en) * | 2005-03-18 | 2013-12-10 | Novo Nordisk A/S | Extended GLP-1 compounds |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US8450270B2 (en) * | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| AR072160A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EP2552951A1 (en) * | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
-
2012
- 2012-03-28 RU RU2013145013/04A patent/RU2013145013A/ru unknown
- 2012-03-28 CN CN201280015759.6A patent/CN103596583B/zh not_active Expired - Fee Related
- 2012-03-28 BR BR112013024076A patent/BR112013024076A2/pt not_active IP Right Cessation
- 2012-03-28 EP EP12710748.0A patent/EP2691108A1/en not_active Withdrawn
- 2012-03-28 AU AU2012234276A patent/AU2012234276A1/en not_active Withdrawn
- 2012-03-28 CA CA2830974A patent/CA2830974A1/en not_active Withdrawn
- 2012-03-28 US US13/984,185 patent/US20140031278A1/en not_active Abandoned
- 2012-03-28 JP JP2014501586A patent/JP2014510739A/ja not_active Withdrawn
- 2012-03-28 KR KR1020137027799A patent/KR20140020292A/ko not_active Withdrawn
- 2012-03-28 WO PCT/EP2012/055481 patent/WO2012130866A1/en not_active Ceased
- 2012-03-28 MX MX2013011175A patent/MX2013011175A/es unknown
-
2013
- 2013-08-08 IL IL227869A patent/IL227869A0/en unknown
- 2013-08-29 ZA ZA2013/06514A patent/ZA201306514B/en unknown
-
2015
- 2015-07-31 US US14/814,686 patent/US20150368313A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103596583B (zh) | 2016-07-27 |
| EP2691108A1 (en) | 2014-02-05 |
| BR112013024076A2 (pt) | 2016-12-06 |
| RU2013145013A (ru) | 2015-05-10 |
| WO2012130866A1 (en) | 2012-10-04 |
| US20140031278A1 (en) | 2014-01-30 |
| US20150368313A1 (en) | 2015-12-24 |
| IL227869A0 (en) | 2013-09-30 |
| MX2013011175A (es) | 2013-11-01 |
| JP2014510739A (ja) | 2014-05-01 |
| CN103596583A (zh) | 2014-02-19 |
| AU2012234276A1 (en) | 2013-08-29 |
| KR20140020292A (ko) | 2014-02-18 |
| CA2830974A1 (en) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231199A0 (en) | New analogs of glucagon | |
| IL232800A0 (en) | Glucagon analog | |
| ZA201702364B (en) | Glucagon analogues | |
| AP3286A (en) | Glucagon analogues | |
| ZA201306514B (en) | Novel glucagon analogues | |
| ZA201206838B (en) | Novel glucagon analogues | |
| IL237518A (en) | Glucagon analog | |
| AP2013006671A0 (en) | Glucagon analogues | |
| ZA201309626B (en) | Glucagon/glp-1 reeptor co-agonists | |
| EP2662268A4 (en) | CAP MOUNTING STRUCTURE | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| AU342272S (en) | Watchcase | |
| GB201119167D0 (en) | Novel bachteriophages | |
| ZA201403228B (en) | Heterocyclypyri(mi)dinylpyrazole | |
| ZA201402298B (en) | Heterocyclylpyri (mi)dinylpyrazole as fungicidals | |
| PT2780505T (pt) | Filtro | |
| EP2751367A4 (en) | LADDER | |
| EP2753434A4 (en) | SIEVE | |
| SG11201402471SA (en) | Photocatalyst-supporting structure | |
| ZA201109401B (en) | Screen | |
| CL2014001638A1 (es) | Analogos de glucagon | |
| CO7061032A2 (es) | Análogos de glucagón | |
| GB201101572D0 (en) | Peg | |
| GB201108226D0 (en) | Peg | |
| GB201107854D0 (en) | Novel 5-hydroxy-5-aryl-pyrrol-2-ones |